Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ACTRN12626000615381) titled 'A trial to assess the safety, tolerability and efficacy of RES-010 in overweight and obese adults without obesity-related comorbidities' on May 19.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Type of endpoint: Safety/efficacy
Primary Sponsor: Resalis Therapeutics Australia Pty Ltd
Condition:
Obesity (Mild)
Overweight
Obesity (Mild)
Overweight
Diet and Nutrition - Obesity
Intervention:
This study aims to find out if the study drug, RES-010, is safe and tolerable, and if RES-010 can help with weight loss.
This is a dose escalation study, which mean...